Drug intelligence / Profile preview

5-fluorouracil + conjugated estrogens

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of 5-fluorouracil, a pyrimidine analog that acts as an antimetabolite chemotherapeutic agent, and conjugated estrogens, a mixture of estrogen hormones. This combination has been studied in clinical trials for the treatment of breast cancer, with research showing that physiologic doses of conjugated estrogens did not negatively influence the course of the disease when combined with 5-fluorouracil.

Targets

ER (Estrogen receptor)TS (Thymidylate synthase)

Beyond the preview

Go deeper on 5-fluorouracil + conjugated estrogens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + conjugated estrogens.

Explore the full profile